Today’s Research Reports on Stocks to Watch: Achillion Pharmaceuticals and Corbus Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / March 31, 2017 / Achillion’s stock yesterday were not as volatile as Wednesday with the value increasing by the close of business yesterday. Corbus Pharma is also struggling, but the positive results from the second phase of the clinical drug trials are set to shed some optimistic light on the company’s stock going forward.

RDI Initiates
Coverage:

Achillion
Pharmaceuticals, Inc. https://ub.rdinvesting.com/news/?ticker=ACHN

Corbus
Pharmaceuticals Holdings Inc. https://ub.rdinvesting.com/news/?ticker=CRBP

Achiullion Pharmaceuticals stock closed yesterday on a high, with the share price increasing marginally. The company’s stock closed at $4.28, a 0.23% rise from the previous closing. It has been a month since the company released its latest earnings report and the stock value has plummeted 11.3%, with the data indicating underperformance of the stock in terms of trade volume. Achillion’s EPS dipped 0.03% during the fourth quarter financial period. The company’s Q4 revenue was reduced by half, reporting $15 million, compared to $31.6 million registered a year ago.

The company’s expenses increased, with overall spending on drug trials, manufacturing and consulting costs making up the majority of the operating expenses of $15 million. Analysts have remained quiet on the company’s 2017 estimates. The company is still struggling to offset competition, facilitate clinical trials.

Access RDI’s Achillion Pharmaceuticals Research Report
at: https://ub.rdinvesting.com/news/?ticker=ACHN

The company’s stock struggled to remain on the green yesterday, to close at $7.95. By midday, the price had shot up to register highs of $8.45, but this barely lasted until 4pm. The phase 2 study of the clinical drug trial is now complete, after completion of the phase 1 study a fortnight ago. The results were positive, with the probability rate of success on the Cystic Fibrosis research going up by 50% from 30%.

The additional funds boosted the research’s success probability. The company announced that the main focus of the phase 2 study is to ensure the patients’ safety. The company is working to ensure that the patient’s condition does not deteriorate due to therapeutic procedures.

Access RDI’s Corbus Pharmaceuticals Research Report at: https://ub.rdinvesting.com/news/?ticker=CRBP

Our Actionable Research on Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) and Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458639